Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1066001 | 0.98 | L3MBTL1 (0.55) | L3MBTL1EPHX1KDM4EALDH1A1TDP1 | |
| SCHEMBL27923823 | 0.90 | L3MBTL1 (0.42) | L3MBTL1EPHX1KDM4EALDH1A1TDP1 | |
| SCHEMBL306905 | 0.83 | L3MBTL1 (0.48) | L3MBTL1EPHX1KDM4EALDH1A1TDP1 | |
| Hydrochloric Acid SCHEMBL31327376 | 0.82 | L3MBTL1 (0.50) | L3MBTL1EPHX1KDM4EALDH1A1TDP1 | |
| SCHEMBL18973529 | 0.81 | EPHX1 (0.44) | L3MBTL1EPHX1KDM4EALDH1A1CYP1A2 | |
| SCHEMBL5950988 | 0.81 | L3MBTL1 (0.49) | L3MBTL1EPHX1KDM4EALDH1A1TDP1 | |
| Hydrochloric Acid SCHEMBL1067742 | 0.80 | L3MBTL1 (0.51) | L3MBTL1EPHX1KDM4EALDH1A1TDP1 | |
| SCHEMBL16092908 | 0.78 | L3MBTL1 (0.47) | L3MBTL1EPHX1KDM4EALDH1A1TDP1 | |
| SCHEMBL25623301 | 0.78 | L3MBTL1 (0.47) | L3MBTL1EPHX1KDM4EALDH1A1TDP1 | |
| SCHEMBL4713945 | 0.78 | ALDH1A1 (0.45) | KDM4EALDH1A1TDP1SMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1602362-B1 | DRUG COMPOSITION HAVING ACTIVE INGREDIENT ADHERED AT HIGH CONCENTRATION TO SPHERICAL CORE | TAKEDA PHARMACEUTICAL (JP) | 2016-09-28 | — | — | EP | disclosed |
| US-20160128945-A1 | CONTROLLED RELEASE PREPARATION | TAKEDA PHARMACEUTICAL (JP) | 2016-05-12 | — | — | US | disclosed |
| US-8784885-B2 | Controlled release preparation | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-22 | — | — | US | disclosed |
| US-8784885-B2 | Controlled release preparation | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-22 | — | — | US | disclosed |
| US-20140186449-A1 | CONTROLLED RELEASE PREPARATION | TAKEDA PHARMACEUTICAL (JP) | 2014-07-03 | — | — | US | disclosed |
| US-20140186448-A1 | CONTROLLED RELEASE PREPARATION | TAKEDA PHARMACEUTICAL (JP) | 2014-07-03 | — | — | US | disclosed |
| US-8722084-B2 | Controlled release preparation | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-05-13 | — | — | US | disclosed |
| US-8722084-B2 | Controlled release preparation | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-05-13 | — | — | US | disclosed |
| US-8449911-B2 | Drug composition having active ingredient adhered at high concentration to spherical core | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-28 | — | — | US | disclosed |
| US-8449911-B2 | Drug composition having active ingredient adhered at high concentration to spherical core | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-28 | — | — | US | disclosed |
| US-20100278911-A1 | CONTROLLED RELEASE PREPARATION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-04 | — | — | US | disclosed |
| US-20100272798-A1 | CONTROLLED RELEASE PREPARATION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-28 | — | — | US | disclosed |
| US-20100272798-A1 | CONTROLLED RELEASE PREPARATION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-28 | — | — | US | disclosed |
| US-7790755-B2 | dexlansoprazole FDA Orange book listed patent; capsules with pH dependently soluble polymers such as methyl methacrylate-methacrylic acid copolymers or cellulose esters | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-07 | — | — | US | disclosed |
| US-7790755-B2 | dexlansoprazole FDA Orange book listed patent; capsules with pH dependently soluble polymers such as methyl methacrylate-methacrylic acid copolymers or cellulose esters | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-07 | — | — | US | disclosed |
| EP-1513527-B1 | PRODRUGS OF IMIDAZOLE DERIVATIVES, FOR USE AS PROTON PUMP INHIBITORS IN THE TREATMENT OF E.G. PEPTIC ULCERS | TAKEDA PHARMACEUTICAL (JP) | 2009-07-29 | — | — | EP | disclosed |
| US-7410981-B2 | Prodrugs of imidazole derivatives, for use as proton pump inhibitors in the treatment of e.g. peptic ulcers | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-12 | — | — | US | disclosed |
| US-7410981-B2 | Prodrugs of imidazole derivatives, for use as proton pump inhibitors in the treatment of e.g. peptic ulcers | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-12 | — | — | US | disclosed |
| US-20060159760-A1 | Drug composition having active ingredient adhered at high concentration to spherical core | AOYAMA & PARTNERS | 2006-07-20 | — | — | US | disclosed |
| EP-1602362-A1 | DRUG COMPOSITION HAVING ACTIVE INGREDIENT ADHERED AT HIGH CONCENTRATION TO SPHERICAL CORE | Takeda Pharmaceutical Company Limited (JP) | 2005-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100272798-A1 | CONTROLLED RELEASE PREPARATION | SLC18A1, MLN, GCG | L3MBTL1 4751/4885EPHX1 2986/4885KDM4E 3684/4885 |
| US-20160128945-A1 | CONTROLLED RELEASE PREPARATION | SLC18A1, MLN, GCG | L3MBTL1 4751/4885EPHX1 2986/4885KDM4E 3684/4885 |
| US-20100278911-A1 | CONTROLLED RELEASE PREPARATION | SLC18A1, MLN, GCG | L3MBTL1 4751/4885EPHX1 2986/4885KDM4E 3684/4885 |
| US-20060159760-A1 | Drug composition having active ingredient adhered at high concentration to spherical core | SLC18A1, MAST1, ABCG2 | L3MBTL1 4213/4885EPHX1 2578/4885KDM4E 1766/4885 |
| US-20140186449-A1 | CONTROLLED RELEASE PREPARATION | SLC18A1, MLN, GCG | L3MBTL1 4751/4885EPHX1 2986/4885KDM4E 3684/4885 |
| US-20140186448-A1 | CONTROLLED RELEASE PREPARATION | SLC18A1, MLN, GCG | L3MBTL1 4751/4885EPHX1 2986/4885KDM4E 3684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.